MDxHealth SA (MDXH) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement...

Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26

Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance

            MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue...

MDxHealth to Participate in Piper Sandler Healthcare Conference

MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024

Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6

MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

MDxHealth Announces Pricing of Offering of Ordinary Shares

MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25...